New shot aims to block tetanus after cuts and wounds
NCT ID NCT07347938
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new medicine called siltartoxatug to prevent tetanus in people who have been injured. About 6,000 adults in China will receive either the new drug or a standard tetanus shot. Researchers will check how well each treatment prevents tetanus over 90 days and monitor for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
siltartoxatug injection
What this could lead to
If successful, siltartoxatug could offer a new, effective option to prevent tetanus after injuries, potentially with fewer side effects than current treatments.
What could go wrong
This is a Phase 4 study, so the drug is already approved, but it is still being tested in a large real-world setting. There is always a risk of unexpected side effects or that it may not be as effective as existing options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TETANUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••